Number of eligible patients: CDEC discussed the uncertainty in the number of individuals with moderately extreme to extreme hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some individuals who are categorised as having moderate or average ailment could have a extreme bleeding phe